Motion (Satinamide Add-On To Dopamine Agonist in Early Idiopathic Parkinson's Disease) Study Design: A 24-Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Safinamide
                        AuthID
P-016-ZPJ
                
    P-016-ZPJ
 
    
                    